Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220865079> ?p ?o ?g. }
- W4220865079 endingPage "95" @default.
- W4220865079 startingPage "86" @default.
- W4220865079 abstract "Abstract: Rheumatoid arthritis (RA) is the most common musculoskeletal disease in the world. The clinical prospects have increased tremendously since the advent of biological agents as therapy options. NSAIDs such as indomethacin, celecoxib, and etoricoxib are used often in the treatment of RA but off-target effects decreased their use. DMARDs such as methotrexate and etanercept were also effective in the treatment of RA, but tolerance to methotrexate developed in many cases. Janus kinase inhibitors (JAKi) have also gained popularity as a treatment option for rheumatoid arthritis. Tofacitinib is the foremost JAK inhibitor that is used to treat RA as an individual agent or in combination with other DMARDs. The most frequently used route of administration for JAKi is oral. Since oral formulations of JAK inhibitors have a number of health hazards, such as systemic toxicity and patient noncompliance, topical formulations of JAK inhibitors have emerged as a preferable alternative for administering JAK inhibitors. Tofacitinib delivered topically, seems to have the potential to eliminate or reduce the occurrences of negative effects when compared to tofacitinib taken orally. Given the scarcity of knowledge on the techniques for topical distribution of JAKi, more effort will be required to develop a stable topical formulation of JAKi to address the limitations of oral route. The current review looks at JAK inhibitors and the ways that have been used to generate topical formulations of them." @default.
- W4220865079 created "2022-04-03" @default.
- W4220865079 creator A5025352480 @default.
- W4220865079 creator A5037780530 @default.
- W4220865079 creator A5051928333 @default.
- W4220865079 creator A5083755351 @default.
- W4220865079 date "2022-04-01" @default.
- W4220865079 modified "2023-09-27" @default.
- W4220865079 title "Rheumatoid Arthritis and JAK-STAT Inhibitors: Prospects of Topical Delivery" @default.
- W4220865079 cites W149177015 @default.
- W4220865079 cites W1541129354 @default.
- W4220865079 cites W1660988713 @default.
- W4220865079 cites W1960396018 @default.
- W4220865079 cites W1967167881 @default.
- W4220865079 cites W1970011553 @default.
- W4220865079 cites W1973454407 @default.
- W4220865079 cites W1974032459 @default.
- W4220865079 cites W1975202136 @default.
- W4220865079 cites W1980927217 @default.
- W4220865079 cites W1981674391 @default.
- W4220865079 cites W1985238647 @default.
- W4220865079 cites W2002220979 @default.
- W4220865079 cites W2003273054 @default.
- W4220865079 cites W2006344722 @default.
- W4220865079 cites W2021058637 @default.
- W4220865079 cites W2029275361 @default.
- W4220865079 cites W2030922722 @default.
- W4220865079 cites W2038593306 @default.
- W4220865079 cites W2046503049 @default.
- W4220865079 cites W2054717635 @default.
- W4220865079 cites W2056445309 @default.
- W4220865079 cites W2058898205 @default.
- W4220865079 cites W2062043116 @default.
- W4220865079 cites W2064704364 @default.
- W4220865079 cites W2072171359 @default.
- W4220865079 cites W2074817486 @default.
- W4220865079 cites W2075455573 @default.
- W4220865079 cites W2077550414 @default.
- W4220865079 cites W2079557777 @default.
- W4220865079 cites W2081130105 @default.
- W4220865079 cites W2094712256 @default.
- W4220865079 cites W2096906176 @default.
- W4220865079 cites W2101840353 @default.
- W4220865079 cites W2110826367 @default.
- W4220865079 cites W2115421980 @default.
- W4220865079 cites W2121008892 @default.
- W4220865079 cites W2121219094 @default.
- W4220865079 cites W2131666890 @default.
- W4220865079 cites W2132173287 @default.
- W4220865079 cites W2132776121 @default.
- W4220865079 cites W2140611998 @default.
- W4220865079 cites W2142924005 @default.
- W4220865079 cites W2149476900 @default.
- W4220865079 cites W2150129386 @default.
- W4220865079 cites W2152824905 @default.
- W4220865079 cites W2156374015 @default.
- W4220865079 cites W2158649716 @default.
- W4220865079 cites W2159659449 @default.
- W4220865079 cites W2163087340 @default.
- W4220865079 cites W2164224372 @default.
- W4220865079 cites W2164716517 @default.
- W4220865079 cites W2214195401 @default.
- W4220865079 cites W2216337048 @default.
- W4220865079 cites W2272685247 @default.
- W4220865079 cites W2300599593 @default.
- W4220865079 cites W2314184306 @default.
- W4220865079 cites W2338269660 @default.
- W4220865079 cites W2351171987 @default.
- W4220865079 cites W2440619558 @default.
- W4220865079 cites W2481496926 @default.
- W4220865079 cites W2514636758 @default.
- W4220865079 cites W2529297032 @default.
- W4220865079 cites W2562753811 @default.
- W4220865079 cites W2566103724 @default.
- W4220865079 cites W2566974850 @default.
- W4220865079 cites W2593565645 @default.
- W4220865079 cites W2607343491 @default.
- W4220865079 cites W2748325380 @default.
- W4220865079 cites W2765975325 @default.
- W4220865079 cites W2767394258 @default.
- W4220865079 cites W2782968698 @default.
- W4220865079 cites W2800246801 @default.
- W4220865079 cites W2800650671 @default.
- W4220865079 cites W2802137035 @default.
- W4220865079 cites W2803973097 @default.
- W4220865079 cites W2803975545 @default.
- W4220865079 cites W2807791746 @default.
- W4220865079 cites W2844015770 @default.
- W4220865079 cites W2898555886 @default.
- W4220865079 cites W2899259208 @default.
- W4220865079 cites W2899280240 @default.
- W4220865079 cites W2902100474 @default.
- W4220865079 cites W2905252141 @default.
- W4220865079 cites W2908728730 @default.
- W4220865079 cites W2913263286 @default.
- W4220865079 cites W2914209107 @default.
- W4220865079 cites W2933412269 @default.
- W4220865079 cites W2936120062 @default.